Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutationsChen Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Yu Zhang(Union Hospital)Acta Pharmaceutica Sinica BMarch 10, 202310.1016/j.apsb.2023.03.007Cited by 10SaveCiteExport RISWatch citationsRelated PapersPolyethylene glycol loxenatide protects diabetic kidneys by inhibiting GRP78/PERK/eIF2α pathway, and improves cardiac injury by suppressing TLR4/NF-κB inflammatory pathway|BMC Cardiovascular Disorders|2024|8Enhancing cellular morphological changes and ablation of cancer cells <i>via</i> the interaction of drug co-loaded magnetic nanosystems in weak rotating magnetic fields|RSC Advances|2020|4